CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer

Tempfer, Clemens B.; Sliutz, Gerhard; Haeusler, G.; Speiser, Paul; Reinthaller, Alexander; Breitenecker, G.; Vavra, N.; Kainz, Christian

doi:10.1038/bjc.1998.633

Cited by 15 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In three pilot studies involving 30, 25, and 35 cases of primary vulvar carcinoma of different stages, CD44v3 and CD44v6 were associated with poor prognosis 9, 10, 12. Another study examined the immunohistochemically detected expression of CD44 in vulvar carcinoma FIGO Stage I 11. A major shortcoming of these studies was the absence of the availability of a groin lymph node status11 and the low number of patients 9, 10, 12.…”

Section: Discussionmentioning

confidence: 99%

“…Immunohistochemic staining for CD44v3 and CD44v6 was performed as described previously 11. Widespread staining of > 50% of the tumor cells was interpreted as positive, staining of < 50% of the tumor cells was interpreted as negative (Figure 1A and B).…”

Section: Methodsmentioning

confidence: 99%

“…together and a consensus was reached. Positive and negative controls were used as described previously 11…”

Section: Methodsmentioning

confidence: 99%

“…In vulvar carcinoma, the correlation between immunohistochemically detected expression of the CD44 isoforms CD44standard, CD44v3, and CD44v6 and prognosis has been previously investigated 9–12. Of those isoforms, CD44v3 and CD44v6 were shown to predict lymph node involvement and poor prognosis in univariate analyses.…”

mentioning

confidence: 99%

See 3 more Smart Citations

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

Hefler

Concin

Mincham

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND Isoforms of the adhesion molecule CD44 are involved in carcinogenesis and the metastatic cascade of tumor cells by increasing the affinity of malignant cells to their extracellular matrix. Preliminary data with respect to the prognostic value of the CD44 isoforms CD44v3 and CD44v6 in patients with vulvar carcinoma showed promising results. The current multicenter study aimed to determine the prognostic value of CD44v3 and CD44v6 in patients with surgically staged vulvar carcinoma. METHODS Expression of CD44v3 and CD44v6 in vulvar carcinoma tissue was assessed by immunohistochemistry. Immunohistochemic staining was performed according to established protocols. Results were correlated to clinical data. RESULTS A positive CD44v3 and CD44v6 staining was detected in 33.3% (33 out of 99) and 39.4% (39 out of 99) of the tumor samples, respectively. Overexpression of CD44v6 was associated with an impaired prognosis with respect to disease‐free survival (P = 0.01) and overall survival (P = 0.04). Multivariate analysis showed that CD44v6 provided prognostic information with respect to disease‐free survival (P = 0.001) and overall survival (P = 0.005) independently of the two established prognosticators, tumor stage and groin lymph node involvement. Overexpression of CD44v3 had no impact on patient survival. CONCLUSIONS The current multicenter study, involving a large series of patients with surgically staged vulvar carcinoma, allowed for multivariate survival analysis and showed that CD44v6 confers prognostic information in addition to that provided by the established clinicopathologic parameters of tumor stage and lymph node status. Cancer 2002;94:125–30. © 2002 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…together and a consensus was reached. Positive and negative controls were used as described previously 11…”

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

Hefler

Concin

Mincham

et al. 2001

Cancer

View full text Add to dashboard Cite

show abstract

“…In contrast to our findings, others have found significant associations between CD44v3 and tumour development or prognosis. [10][11][12] This inconsistency may be due to heterogeneity within the tumour itself, different standards for evaluating staining, or variations in antibody specificity or sensitivity.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer

Zhang

et al. 2015

J Int Med Res

View full text Add to dashboard Cite

Objectives: To evaluate levels of CD44 standard variant (CD44s), CD44 variant exon 3 (CD44v3) and CD44 variant exon 6 (CD44v6) protein in breast cancer tissue, and investigate their relationships with clinicopathological characteristics of the disease. Methods: Immunohistochemistry for CD44s, CD44v3 and CD44v6 was retrospectively performed on formalin-fixed paraffin wax-embedded breast cancer tissue samples. Results: Tumour tissue samples from 60 patients with breast cancer were included. There was a significant relationship between CD44s positivity and tumour diameter and lymph node involvement. CD44v6 positivity was significantly associated with tumour-node-metastasis (TNM) stage and lymph node involvement. There were significant negative correlations between CD44s immunopositivity, tumour diameter and TNM stage, and significant positive correlations between CD44v6 immunopositivity, tumour diameter and TNM stage. Conclusions: CD44s and CD44v6 appear to play opposing roles in the development of breast cancer, but their precise functions and mechanisms of action remain unclear.

show abstract

Vulvar Cancer

Benedet¹,

Ehlen²

2014

TNM Online

View full text Add to dashboard Cite

Vulvar cancer is an uncommon malignancy accounting for approximately 4–5% of all gynecologic cancers. It used to be thought of as predominantly a disease of the elderly, although reports of young, reproductive‐age‐group women with this disease increasingly appear in the literature. The external location of the vulva should prompt early presentation, but traditionally significant delays in diagnosis have been associated with this cancer. The past decade has seen a better understanding of the prognostic factors for vulvar cancer, which, in turn, has led to a more individualized approach to therapy. This has led to less aggressive surgery in the earlier stage of the disease with better cosmetic and functional results. It might be expected that, with the increasing life expectancy in many countries and the concomitant aging of the population, an increase in the number of cases being diagnosed would occur in the future.

show abstract

CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer

Cited by 15 publications

References 16 publications

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

The prognostic value of immunohistochemically detected CD44v3 and CD44v6 expression in patients with surgically staged vulvar carcinoma

Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer

Vulvar Cancer

Contact Info

Product

Resources

About